NOL7 (nucleolar protein 7) is an essential component of the small subunit (SSU) processome that coordinates early ribosome biogenesis in human cells 1. As a functional ortholog of yeast Bud21, NOL7 is required for processing of the 5'-external transcribed spacer (5'ETS) sequence and maintenance of early pre-rRNA levels, with depletion triggering nucleolar stress responses and decreased protein synthesis 1. The protein functions through RNA binding and localizes to the nucleolus via a C-terminal nucleolar localization sequence, where it maintains internal nucleolar architecture critical for cell proliferation 2. Beyond its ribosomal role, NOL7 acts as a tumor suppressor through post-transcriptional regulation of angiogenesis-related genes 3. It binds specifically to thrombospondin-1 (TSP-1) mRNA via its 3'UTR, stabilizing the transcript and promoting expression of this endogenous angiogenesis inhibitor 3. Clinically, NOL7 is frequently inactivated in cancers including cervical cancer through loss of heterozygosity and somatic mutations 4. Pancancer analysis reveals elevated NOL7 expression correlates with poor prognosis in multiple tumor types, including hepatocellular carcinoma and ovarian cancer, with dysregulation linked to RNA metabolism pathways 5. These findings establish NOL7 as a dual-function protein essential for ribosome biogenesis and tumor suppression.